X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9429) 9429
Publication (965) 965
Book Review (636) 636
Book Chapter (29) 29
Dissertation (19) 19
Conference Proceeding (16) 16
Magazine Article (4) 4
Data Set (3) 3
Book / eBook (1) 1
Government Document (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8679) 8679
humans (7315) 7315
pharmacology & pharmacy (4923) 4923
male (4308) 4308
cytochrome p-450 cyp3a (3935) 3935
female (3056) 3056
animals (2838) 2838
cytochrome p-450 cyp3a - metabolism (2734) 2734
cytochrome p-450 enzyme system - metabolism (2390) 2390
adult (2360) 2360
metabolism (2200) 2200
pharmacokinetics (2177) 2177
drug interactions (1941) 1941
cytochrome p-450 cyp3a - genetics (1906) 1906
middle aged (1809) 1809
rats (1577) 1577
cytochrome p-450 (1405) 1405
cytochrome p-450 enzyme system - genetics (1274) 1274
cyp3a (1189) 1189
in-vitro (1179) 1179
cyp3a4 (1165) 1165
expression (1120) 1120
toxicology (1119) 1119
microsomes, liver - enzymology (1095) 1095
cytochrome p450 (1068) 1068
genotype (1025) 1025
cytochrome p-450 enzyme inhibitors (1010) 1010
enzymes (969) 969
aged (965) 965
p-glycoprotein (954) 954
microsomes, liver - metabolism (922) 922
aryl hydrocarbon hydroxylases (918) 918
liver (896) 896
dose-response relationship, drug (893) 893
area under curve (860) 860
liver - enzymology (850) 850
biochemistry & molecular biology (841) 841
cytochrome p-450 cyp3a inhibitors (826) 826
induction (795) 795
enzyme inhibitors - pharmacology (774) 774
microsomes, liver - drug effects (762) 762
rats, sprague-dawley (761) 761
kinetics (759) 759
inhibition (757) 757
analysis (753) 753
liver - metabolism (740) 740
mixed function oxygenases - metabolism (715) 715
administration, oral (714) 714
mice (708) 708
aryl hydrocarbon hydroxylases - metabolism (684) 684
human liver-microsomes (661) 661
young adult (655) 655
midazolam (647) 647
pharmacogenetics (645) 645
liver - drug effects (641) 641
drug-interactions (638) 638
physiological aspects (617) 617
adolescent (606) 606
oxidoreductases, n-demethylating - metabolism (602) 602
biotransformation (601) 601
drug-metabolism (577) 577
identification (573) 573
hydroxylation (564) 564
abridged index medicus (552) 552
research (552) 552
cytochrome p-450 enzyme system - biosynthesis (537) 537
pharmacology (516) 516
chemistry, medicinal (510) 510
chromatography, high pressure liquid (510) 510
pharmacology/toxicology (508) 508
metabolites (500) 500
tacrolimus (494) 494
aryl hydrocarbon hydroxylases - genetics (483) 483
cells, cultured (479) 479
polymorphism, genetic (477) 477
in vitro techniques (458) 458
pregnane x receptor (449) 449
cross-over studies (448) 448
midazolam - pharmacokinetics (444) 444
polymorphism, single nucleotide (436) 436
time factors (436) 436
oncology (435) 435
cyp3a5 (422) 422
enzyme induction - drug effects (419) 419
cyclosporine (418) 418
biological availability (417) 417
ketoconazole (416) 416
rna, messenger - metabolism (416) 416
hepatocytes - drug effects (415) 415
immunosuppressive agents - pharmacokinetics (415) 415
ketoconazole - pharmacology (412) 412
article (407) 407
models, biological (406) 406
hepatocytes - metabolism (392) 392
cytochrome p-450 cyp2d6 - metabolism (391) 391
substrate specificity (391) 391
rat (389) 389
genetic aspects (387) 387
drug metabolism (385) 385
half-life (381) 381
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9183) 9183
Chinese (111) 111
Japanese (52) 52
Spanish (38) 38
Russian (23) 23
German (21) 21
French (20) 20
Hungarian (5) 5
Polish (5) 5
Czech (4) 4
Korean (4) 4
Norwegian (3) 3
Dutch (2) 2
Italian (2) 2
Slovak (2) 2
Danish (1) 1
Finnish (1) 1
Romanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Clinical Pharmacology, ISSN 0031-6970, 7/2018, Volume 74, Issue 7, pp. 913 - 920
Cytochrome P450 (CYP) 3A4 is responsible for the metabolism of more than 30% of clinically used drugs. Inherent between subject variability in clearance of... 
Biomedicine | Inter-racial variability | Caucasian | South Asian | Pharmacology/Toxicology | Pharmacokinetics | Inducibility | Cytochrome P450 3A4 | MESSENGER-RNA EXPRESSION | INTERINDIVIDUAL VARIABILITY | POPULATIONS | POLYMORPHISM | CYTOCHROME-P450 3A4 | GENOTYPE-PHENOTYPE ASSOCIATIONS | METABOLISM | IN-VIVO | PHARMACOLOGY & PHARMACY | MIDAZOLAM | Rifampin - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Rifampin - blood | Area Under Curve | Humans | Asian Continental Ancestry Group - genetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Cytochrome P-450 CYP3A Inducers - blood | Clarithromycin - blood | Young Adult | Cytochrome P-450 CYP3A - genetics | Clarithromycin - pharmacokinetics | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Adult | Continental Population Groups | European Continental Ancestry Group - genetics | Cytochrome P-450 CYP3A Inhibitors - blood | Enzyme Induction | Genotype | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A Inducers - pharmacology | Midazolam - blood | Cytochrome P-450 CYP3A - metabolism | Rifampin - pharmacology | Clarithromycin - pharmacology | Physiological aspects | Medical colleges | Rifampin | Analysis | Cytochrome P-450 | Cytochrome | Clarithromycin | Statistical analysis | Cytochrome P450 | Variability | Whites | Exposure | Males | Metabolism | Substrates | Midazolam | Genotypes | Asians | Index Medicus
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 6/2014, Volume 70, Issue 6, pp. 675 - 684
ACT-178882, a direct renin inhibitor, was used as a model compound in an elaborate drug–drug interaction study with atorvastatin and simvastatin to explore... 
Biomedicine | ACT-178882 | Induction | Simvastatin | Drug–drug interaction | Atorvastatin | Inhibition | Pharmacology/Toxicology | Drug-drug interaction | DRUG-INTERACTIONS | TESTOSTERONE | ITRACONAZOLE | CLINICAL PHARMACOKINETICS | IN-VITRO | METABOLISM | RELEVANCE | PHARMACOLOGY & PHARMACY | MIDAZOLAM | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Cyclopropanes - blood | Substrate Specificity | Male | Cyclopropanes - adverse effects | Simvastatin - blood | Cytochrome P-450 CYP3A Inducers - adverse effects | Cytochrome P-450 CYP3A Inducers - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Pyridines - adverse effects | Drug Interactions | Cyclopropanes - administration & dosage | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Cyclopropanes - pharmacology | Cytochrome P-450 CYP3A - biosynthesis | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Simvastatin - administration & dosage | Pyrroles - blood | Simvastatin - pharmacokinetics | Cytochrome P-450 CYP3A Inducers - administration & dosage | Pyridines - blood | Cytochrome P-450 CYP3A Inducers - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Pyridines - pharmacology | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Heptanoic Acids - blood | Metabolites | Analysis | Cytochrome P-450 | Dosage and administration | Investigations | Antilipemic agents | Hypertension | Clinical trials | Pharmacology | Inhibitor drugs | Statins | Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2017, Volume 83, Issue 9, pp. 1954 - 1965
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 05/2017, Volume 486, Issue 3, pp. 639 - 644
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6 | Index Medicus
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 06/2015, Volume 55, Issue 6, pp. 708 - 717
Journal Article
Toxicology Letters, ISSN 0378-4274, 09/2018, Volume 294, pp. 27 - 36
The high risk of herb-drug interactions (HDIs) mediated by the herbal medicines and dietary supplements which containing abundant flavonoids had become more... 
Herb-drug interactions (HDIs) | Flavonoids | CYP3A4 | QSAR | SOPHORA-TONKINENSIS | ANTIBACTERIAL | RISK | PIE | HERBS | IN-VITRO | INHIBITION | CYTOCHROME-P450 ENZYMES | GRAPEFRUIT JUICE | TOXICOLOGY | PROBE | Anti-Anxiety Agents - metabolism | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Diazepam - metabolism | Humans | Microsomes, Liver - metabolism | Drugs, Chinese Herbal - pharmacology | Hydroxylation - drug effects | Hepatocytes - metabolism | Drugs, Chinese Herbal - metabolism | Dietary Supplements - analysis | Diazepam - pharmacology | Hepatocytes - cytology | Diazepam - chemistry | Bufanolides - metabolism | Microsomes, Liver - drug effects | Cytochrome P-450 CYP3A Inhibitors - chemistry | Cytochrome P-450 CYP3A - chemistry | Anti-Anxiety Agents - chemistry | Microsomes, Liver - enzymology | Molecular Structure | Hepatocytes - drug effects | Quantitative Structure-Activity Relationship | Food-Drug Interactions | Cells, Cultured | Computational Biology | Anti-Anxiety Agents - pharmacology | Models, Molecular | Cytochrome P-450 CYP3A Inhibitors - metabolism | Cytochrome P-450 CYP3A - metabolism | Drugs, Chinese Herbal - chemistry | Flavonoids - metabolism | Herb-Drug Interactions | Bufanolides - chemistry | Kinetics | Flavonoids - chemistry | Analysis | Drug interactions | Cytochrome P-450 | Dietary supplements | Isoflavones | Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 2016, Volume 44, Issue 8, pp. 1372 - 1380
Asunaprevir (ASV), daclatasvir (DCV), and beclabuvir (BCV) are three drugs developed for the treatment of chronic hepatitis C virus infection. Here, we... 
NS5B POLYMERASE | IN-VITRO | METABOLISM | CYTOCHROME-P450 ENZYMES | HUMAN HEPATOCYTES | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | INDUCTION | EXPRESSION | NS3 PROTEASE INHIBITOR | ASUNAPREVIR BMS-650032 | Cytochrome P-450 CYP3A Inducers - therapeutic use | Isoquinolines - adverse effects | Liver - enzymology | Benzazepines - adverse effects | Humans | RNA, Messenger - metabolism | Cytochrome P-450 CYP3A Inducers - adverse effects | Dose-Response Relationship, Drug | Drug Interactions | Cytochrome P-450 CYP3A - genetics | Liver - drug effects | Midazolam - adverse effects | Biotransformation | Midazolam - therapeutic use | Imidazoles - therapeutic use | Drug Therapy, Combination | Hepatocytes - drug effects | Risk Assessment | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | RNA, Messenger - genetics | Risk Factors | Cells, Cultured | Hepatitis C, Chronic - drug therapy | Algorithms | Indoles - adverse effects | Sulfonamides - therapeutic use | Benzazepines - therapeutic use | Cytochrome P-450 CYP3A - metabolism | Models, Biological | Antiviral Agents - adverse effects | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Indoles - therapeutic use | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Kinetics | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Nonlinear Dynamics | Hepatocytes - enzymology | Index Medicus
Journal Article
Journal Article
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 05/2018, Volume 151, pp. 723 - 739
Journal Article